Illustrative AI review sample — pediatrics

Key Points

1Norwegian NorEPIS prospective surveillance cohort of 1,096 laboratory-confirmed RSV cases under 59 months (2015–2018) identifying risk factors for severe disease; pre-specified severity definition and multiple imputation strengthen validity, but missing palivizumab data and modest ethnic diversity limit generalisability.

Major Issues

Methods: Palivizumab prophylaxis status is not captured; palivizumab is given to high-risk groups (premature infants, congenital heart disease, chronic lung disease) who overlap substantially with the risk groups identified in this study; its omission may confound the estimated effect of gestational age and chronic pulmonary disease on severity.

Methods / Results: The composite severity outcome pools hospitalisation ≥3 days, ICU admission, and oxygen requirement — events of widely differing clinical severity; a child requiring overnight supplemental oxygen is categorised identically to one requiring mechanical ventilation, which may attenuate detection of risk factors specific to the most severe presentations.

Methods: Household smoking is defined by parental self-report at enrolment without validation against carbon monoxide measurement or cotinine levels; exposure misclassification from social desirability bias may attenuate the smoking-severity association.

Risk factors associated with severe disease in respiratory syncytial virus infected children under 5 years of age

Key Points

Major Issues